Total Payments
$4,552
2024 Payments
$174.07
Companies
22
Transactions
65
Medicare Patients
1,303
Medicare Billing
$133,972
Payment Breakdown by Category
Other$3,345 (73.5%)
Food & Beverage$1,207 (26.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Long term medical supply or device loan | $3,345 | 1 | 73.5% |
| Food and Beverage | $1,207 | 64 | 26.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| INTERNATIONAL REHABILITATIVE SCIENCES, INC | $3,345 | 1 | $0 (2023) |
| Biohaven Pharmaceutical Holding Company Ltd. | $179.69 | 6 | $0 (2022) |
| ABBVIE INC. | $155.52 | 9 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $135.73 | 7 | $0 (2024) |
| Collegium Pharmaceutical, Inc. | $112.49 | 6 | $0 (2023) |
| Abbott Laboratories | $90.30 | 5 | $0 (2023) |
| TerSera Therapeutics LLC | $65.36 | 4 | $0 (2022) |
| GRT US Holding, Inc. | $60.85 | 3 | $0 (2022) |
| Amgen Inc. | $56.45 | 3 | $0 (2022) |
| Pacira Pharmaceuticals Incorporated | $51.86 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $174.07 | 10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($91.22) |
| 2023 | $3,514 | 10 | INTERNATIONAL REHABILITATIVE SCIENCES, INC ($3,345) |
| 2022 | $553.49 | 27 | Biohaven Pharmaceutical Holding Company Ltd. ($179.69) |
| 2021 | $309.94 | 18 | Amgen Inc. ($40.90) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/22/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $18.71 | General |
| 09/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Gastroenterology | ||||||
| 06/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Gastroenterology | ||||||
| 04/15/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: NEUROSCIENCE | ||||||
| 04/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Gastroenterology | ||||||
| 02/21/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Gastroenterology | ||||||
| 02/13/2024 | Nalu Medical, Inc. | Nalu Neurostimulation System (Device) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: Pain Management | ||||||
| 02/09/2024 | Boston Scientific Corporation | Intracept (Device) | Food and Beverage | Cash or cash equivalent | $14.33 | General |
| Category: Pain | ||||||
| 01/29/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Gastroenterology | ||||||
| 01/17/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: NEUROSCIENCE | ||||||
| 11/29/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: Gastroenterology | ||||||
| 09/22/2023 | Abbott Laboratories | ETERNA (Device) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: Neuromodulation | ||||||
| 09/19/2023 | INTERNATIONAL REHABILITATIVE SCIENCES, INC | RS-LBG/FBG (Device), RS 4i Plus Sequential Stimulator | Long term medical supply or device loan | Cash or cash equivalent | $3,344.60 | General |
| Category: DME | ||||||
| 08/08/2023 | Pacira Pharmaceuticals Incorporated | Iovera (Device), Zilretta | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: Pain Management | ||||||
| 07/17/2023 | SPR Therapeutics, Inc | SPRINT PNS System (Device) | Food and Beverage | Cash or cash equivalent | $14.50 | General |
| Category: Pain management | ||||||
| 04/24/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 03/14/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $22.18 | General |
| Category: NEUROLOGY | ||||||
| 03/08/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 02/28/2023 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $22.86 | General |
| Category: Opioid Analgesic | ||||||
| 01/18/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/30/2022 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Neuromodulation | ||||||
| 12/19/2022 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $22.67 | General |
| Category: Opioid Analgesic | ||||||
| 12/12/2022 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Analgesic | ||||||
| 11/22/2022 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Neuromodulation | ||||||
| 11/16/2022 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $19.38 | General |
| Category: Opioid Analgesic | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 7 | 360 | 472 | $89,700 | $42,366 |
| 2021 | 8 | 493 | 659 | $128,888 | $57,714 |
| 2020 | 7 | 450 | 529 | $80,695 | $33,891 |
Total Patients
1,303
Total Services
1,660
Medicare Billing
$133,972
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 81 | 125 | $31,250 | $18,991 | 60.8% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 27 | 33 | $13,200 | $8,077 | 61.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 78 | 109 | $21,800 | $6,730 | 30.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 91 | 117 | $17,550 | $5,683 | 32.4% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 30 | 30 | $2,400 | $1,766 | 73.6% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 41 | 46 | $2,300 | $560.87 | 24.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 12 | $1,200 | $558.11 | 46.5% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 74 | 78 | $31,200 | $19,028 | 61.0% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 95 | 108 | $27,000 | $16,599 | 61.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 138 | 235 | $47,000 | $14,634 | 31.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 61 | 75 | $11,250 | $3,143 | 27.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 28 | 30 | $2,780 | $1,199 | 43.1% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 11 | 11 | $2,310 | $1,144 | 49.5% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2021 | 70 | 90 | $4,500 | $1,058 | 23.5% |
| 99484 | Care management services for behavioral health conditions, at least 20 minutes clinical staff time | Office | 2021 | 16 | 32 | $2,848 | $908.44 | 31.9% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 107 | 115 | $28,750 | $17,485 | 60.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 85 | 106 | $20,975 | $5,342 | 25.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 84 | 101 | $8,040 | $4,798 | 59.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 85 | 104 | $15,500 | $3,555 | 22.9% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 14 | 15 | $3,150 | $1,698 | 53.9% |
| 80305 | Testing for presence of drug | Office | 2020 | 63 | 76 | $3,800 | $833.93 | 21.9% |
| 98967 | Telephone assessment and management service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 12 | $480.00 | $178.50 | 37.2% |
About Amber Easley, APRN
Amber Easley, APRN is a Family healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/24/2017. The National Provider Identifier (NPI) number assigned to this provider is 1922548981.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amber Easley, APRN has received a total of $4,552 in payments from pharmaceutical and medical device companies, with $174.07 received in 2024. These payments were reported across 65 transactions from 22 companies. The most common payment nature is "Long term medical supply or device loan" ($3,345).
As a Medicare-enrolled provider, Easley has provided services to 1,303 Medicare beneficiaries, totaling 1,660 services with total Medicare billing of $133,972. Data is available for 3 years (2020–2022), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Lexington, KY
- Active Since 02/24/2017
- Last Updated 06/09/2022
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1922548981
Products in Payments
- RS-LBG/FBG (Device) $3,345
- NURTEC ODT (Drug) $179.69
- RELISTOR (Drug) $135.73
- XTAMPZA (Drug) $76.27
- PROCLAIM (Device) $73.58
- BOTOX (Biological) $71.05
- Prialt (Drug) $65.36
- Qutenza (Drug) $60.85
- UBRELVY (Drug) $60.27
- Aimovig (Biological) $56.45
- Intracept (Device) $49.81
- Zilretta (Drug) $43.42
- AIMOVIG (Biological) $36.76
- Belbuca (Drug) $36.22
- BYFAVO (Drug) $34.07
- Iovera (Device) $32.61
- ZTLido (Drug) $29.32
- BELBUCA (Drug) $26.84
- QULIPTA (Drug) $24.20
- VYEPTI (Biological) $22.18
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Lexington
Alisha Clemons, Aprn, APRN
Family — Payments: $38,192
Family $38,192
Rose Pierson, Arnp, ARNP
Family — Payments: $12,246
Family $12,246
Lauren Maupin, Arnp, Fnp-C, ARNP, FNP-C
Family — Payments: $11,985
Family $11,985
Laura Travis, Aprn, APRN
Family — Payments: $10,435
Family $10,435
Michael Thorarinson, Fnp-Bc, FNP-BC
Family — Payments: $10,409
Family $10,409
Rhiannon Black, Aprn, APRN
Family — Payments: $9,756
Family $9,756